Last reviewed · How we verify
Methicillin-Resistant Staphylococcus Aureus Nasal Colonization — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Bactroban | MUPIROCIN | GSK | RNA Synthetase Inhibitor Antibacterial | Isoleucine--tRNA ligase, cytoplasmic | 1987-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- GSK · 1 drug in Methicillin-Resistant Staphylococcus Aureus Nasal Colonization
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Methicillin-Resistant Staphylococcus Aureus Nasal Colonization:
- Methicillin-Resistant Staphylococcus Aureus Nasal Colonization treatment updates — RSS
- Methicillin-Resistant Staphylococcus Aureus Nasal Colonization treatment updates — Atom
- Methicillin-Resistant Staphylococcus Aureus Nasal Colonization treatment updates — JSON
Cite this brief
Drug Landscape (2026). Methicillin-Resistant Staphylococcus Aureus Nasal Colonization — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/methicillin-resistant-staphylococcus-aureus-nasal-colonization. Accessed 2026-06-10.
Related
- Methicillin-Resistant Staphylococcus Aureus Nasal Colonization full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing